Thank you, Chair.
Mr. Brougham, thanks for shedding some light on New Zealand pharmacare.
Since you have worked on both sides, can you explain some of the strengths and weaknesses of the Canadian Agency for Drugs and Technologies in Health compared with the therapeutics advisory committee? How could Canada move forward to ensure we are making the most informed decisions for a national pharmacare formulary? You were talking about Ontario, but how could we move forward so everybody could benefit?